Techno Medica Co., Ltd. (TYO:6678)
Japan · Delayed Price · Currency is JPY 2,048.00
+53.00 (2.66%)
Aug 6, 2026, 12:34 PM JST
Techno Medica Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 11,236 | 9,905 | 10,283 | 9,367 | 9,699 | |
Revenue Growth | 13.44% | -3.68% | 9.78% | -3.42% | 7.29% |
Cost of Revenue | 5,994 | 4,978 | 5,131 | 4,738 | 4,882 |
Gross Profit | 5,242 | 4,927 | 5,152 | 4,629 | 4,817 |
Selling, General & Admin | 3,061 | 2,886 | 2,747 | 2,573 | 2,516 |
Research & Development | 462 | 690 | 516 | 369 | 405 |
Operating Expenses | 3,574 | 3,627 | 3,312 | 2,980 | 2,980 |
Operating Income | 1,668 | 1,300 | 1,840 | 1,649 | 1,837 |
Interest & Investment Income | 17 | 6 | - | 1 | 2 |
Currency Exchange Gain (Loss) | 12 | -15 | 2 | - | 6 |
Other Non Operating Income (Expenses) | 19 | 12 | 27 | 17 | 5 |
EBT Excluding Unusual Items | 1,716 | 1,303 | 1,869 | 1,667 | 1,850 |
Gain (Loss) on Sale of Assets | - | - | -9 | - | - |
Asset Writedown | - | - | - | -2 | - |
Other Unusual Items | -192 | 16 | - | - | - |
Pretax Income | 1,524 | 1,319 | 1,860 | 1,665 | 1,850 |
Income Tax Expense | 454 | 315 | 512 | 515 | 569 |
Net Income | 1,070 | 1,004 | 1,348 | 1,150 | 1,281 |
Net Income to Common | 1,070 | 1,004 | 1,348 | 1,150 | 1,281 |
Net Income Growth | 6.57% | -25.52% | 17.22% | -10.23% | 11.10% |
Shares Outstanding (Basic) | 7 | 7 | 8 | 8 | 8 |
Shares Outstanding (Diluted) | 7 | 7 | 8 | 8 | 8 |
Shares Change | -0.40% | -11.17% | -7.64% | -0.64% | 0.01% |
EPS (Basic) | 155.14 | 144.99 | 172.93 | 136.26 | 150.81 |
EPS (Diluted) | 155.14 | 144.99 | 172.93 | 136.26 | 150.81 |
EPS Growth | 7.00% | -16.16% | 26.92% | -9.65% | 11.09% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 1,065 | 952 | 1,105 | 754 | 1,996 |
Free Cash Flow Per Share | 154.41 | 137.48 | 141.76 | 89.34 | 234.98 |
Gross Margin | 46.65% | 49.74% | 50.10% | 49.42% | 49.66% |
Operating Margin | 14.85% | 13.13% | 17.89% | 17.60% | 18.94% |
Profit Margin | 9.52% | 10.14% | 13.11% | 12.28% | 13.21% |
Free Cash Flow Margin | 9.48% | 9.61% | 10.75% | 8.05% | 20.58% |
EBITDA | 1,760 | 1,399 | 1,952 | 1,757 | 1,957 |
EBITDA Margin | 15.66% | 14.12% | 18.98% | 18.76% | 20.18% |
D&A For EBITDA | 92 | 99 | 112 | 108 | 120 |
EBIT | 1,668 | 1,300 | 1,840 | 1,649 | 1,837 |
EBIT Margin | 14.85% | 13.13% | 17.89% | 17.60% | 18.94% |
Effective Tax Rate | 29.79% | 23.88% | 27.53% | 30.93% | 30.76% |